about
Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?Novel psychoactive substances in young adults with and without psychiatric comorbidities.Unraveling exercise addiction: the role of narcissism and self-esteem.Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis.Novel psychoactive substance consumption is more represented in bipolar disorder than in psychotic disorders: A multicenter-observational study.The RS685012 Polymorphism of ACCN2, the Human Ortholog of Murine Acid-Sensing Ion Channel (ASIC1) Gene, is Highly Represented in Patients with Panic Disorder.Substance use, medication adherence and outcome one year following a first episode of psychosis.Abnormal illness behavior and Internet addiction severity: The role of disease conviction, irritability, and alexithymiaTreated Incidence of Psychotic Disorders in the Multinational EU-GEI Study.Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study.188. Does Cannabis Use Worsen Psychotic Symptom Presentation?T110. FIRST EPISODE PSYCHOTIC PATIENTS WITH A HISTORY OF FREQUENT CANNABIS USE EXPRESS MORE POSITIVE SYMPTOMS AT ILLNESS ONSET THAN THOSE WHO NEVER USED CANNABIS.5.4 BIOLOGICAL AND EPIDEMIOLOGICAL EXAMINATION OF TRANSDIAGNOSTIC AND SPECIFIC SYMPTOM DIMENSIONS AT PSYCHOSIS ONSET: FINDINGS FROM THE EUGEI STUDY.35.4 A PUBLIC HEALTH APPROACH TO THE PREVENTION OF PSYCHOSIS.58.1 Cannabis use Across Europe: A Ticket to Psychosis?F99. FIRST EPISODE PSYCHOSIS PATIENTS WHO USED CANNABIS DEVELOP THEIR ILLNESS AT A SIGNIFICANTLY YOUNGER AGE THAN THOSE WHO NEVER USED CONSISTENTLY ACROSS EUROPE AND BRAZIL.O12.4. SOME OF THE INDIVIDUAL DIFFERENCES IN RISK TO DEVELOP PSYCHOSIS AMONG CANNABIS USERS CAN BE EXPLAINED BY WHERE THEY LIVE AND BY THEIR AGE AT FIRST USE.F68. PREMORBID IQ, EDUCATIONAL LEVEL AND JUMPING TO CONCLUSIONS AS PREDICTORS OF CLINICAL OUTCOME AT FIRST ONSET OF PSYCHOSIS OVER THE NEXT 4 YEARS: THE GAP STUDY.S77. JUMPING TO CONCLUSIONS AND FACIAL EMOTION RECOGNITION IMPAIRMENT IN FIRST EPISODE PSYCHOSIS ACROSS EUROPE.O2.1. FIRST EPISODE PSYCHOSIS PATIENTS ACROSS EUROPE DIFFER IN INTELLECTUAL QUOTIENT (IQ) AND EXPOSURE TO ENVIRONMENTAL HAZARDS.Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI studyThe contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control studyJumping To Conclusions, General Intelligence, And Psychosis Liability: Findings From The Multicentric EU-GEI Case-Control StudyCannabis-associated symptom profiles in patients with first episode psychosis and population controlsLetter to the editor: Is polygenic risk for Parkinson's disease associated with less risk of first episode psychosis?Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control studyDoes Personality Matter? Temperament and Character Dimensions in Panic SubtypesIQ differences between patients with first episode psychosis in London and Palermo reflect differences in patterns of cannabis useEarly Parental Death and Risk of Psychosis in Offspring: A Six-Country Case-Control StudyDifferential gene expression analysis in blood of first episode psychosis patientsThe Relationship Between Polygenic Risk Scores and Cognition in SchizophreniaThe EUropean Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI): Incidence and First-Episode Case-Control Programme
P50
Q28109603-4A8C39DA-D829-4245-A783-09BD876656DDQ34009299-42A41722-2E59-435F-8BBB-C27198AFEEA9Q34487664-44BFAA97-8186-4563-BCE0-06F6F34D0EA5Q37274656-C2785959-C972-452C-8301-3805C1C3CBABQ38778976-2144AAB4-725E-413D-B37F-5F700F4E205AQ38940622-658A0A40-F84E-4C7A-921B-A4B81A4F91A0Q40157599-7E6AD784-6DF0-4D5E-A962-DCBE87270FB4Q41531565-BCE15F25-E385-48A1-AEDA-E4E4C328E8C4Q47566854-16290EFD-1779-4F95-8461-EF28FB7B86A1Q47702704-7A95A80D-666B-4874-862E-54DF7A9ECE14Q54841685-0EA39BDE-A8FD-4C03-BE3C-1C50365CB837Q54944099-FDB67CB7-BB46-4381-9C36-85D19559E65AQ55004251-2D0EFA7E-A892-4F24-A9AC-F9BE0E26D6FDQ55017355-9D268DAE-18D8-489C-9199-040D02B9DD29Q55026510-3F75E047-28A4-4432-BC35-3AB228003B7BQ55029016-605F04D1-58FC-4883-A22F-FAA9AA1492FEQ55065521-A2BF5386-4892-41D2-8CF8-5576B870E1D0Q55260087-4C8986DD-2F59-4951-874E-DB4003176FF2Q55317562-6FDF6CC0-2F63-455A-982E-5E53718BF900Q55369814-0ED2A758-EA47-4523-B351-ECA387A39BAFQ57031593-50B2DC07-9434-4491-9C9E-949A154389FDQ62514982-B456AB26-EE19-46D0-82F5-20508422A468Q63869707-47DADD21-EFBD-4F3E-B431-AA0D7C0AA033Q63869708-CF631589-94C9-411E-975A-0A42D52E9873Q90166793-0A523AC2-2EBF-493C-8BD2-384DB3C5B1D5Q90404155-9173A7A6-2081-4E1D-AC9D-9A8744A4897CQ90950301-BA60FEE3-3650-4A4D-A864-E77C1BB4C681Q91619518-51C51A41-3F8C-4D45-9DF8-0E6D4B9E5500Q92150316-E1917556-7755-4B92-A3F3-05BF8A698EE4Q92197348-5F2E3420-F125-4CDB-857C-C49FD78B9B06Q92801122-ED5E7619-AE45-44CF-9948-91225B349007Q92892735-611A64B3-91E6-4ED1-B018-E79E948AD881
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Diego Quattrone
@ast
Diego Quattrone
@en
Diego Quattrone
@es
Diego Quattrone
@sl
type
label
Diego Quattrone
@ast
Diego Quattrone
@en
Diego Quattrone
@es
Diego Quattrone
@sl
prefLabel
Diego Quattrone
@ast
Diego Quattrone
@en
Diego Quattrone
@es
Diego Quattrone
@sl
P106
P1153
8900019500
P21
P31
P496
0000-0002-6051-8309